CandlesenseCandlesense
News/Companies/GUTS

GUTS News

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

GUTS

BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the second quarter 2025 and provide business updates on Tuesday, August 12, 2025, at 4:30 p.m. ET.

August 6, 2025Earnings
Read more →

Fractyl, Bariendo Ink LOI To Develop Scalable Clinical Pathway For Revita In Metabolic Endoscopy Centers Nationwide

GUTS

June 4, 2025
Read more →

Fractyl Health Submits First Module Of Clinical Trial Application In Europe For RJVA-001, Gene Therapy Candidate From Rejuva Platform

GUTS

May 19, 2025
Read more →

Reported Saturday, Fractyl Health Showcases Preclinical Rejuva Data At ASGCT 2025 Demonstrating Durable Metabolic Benefits With Low Systemic GLP-1 Exposure

GUTS

May 19, 2025
Read more →

Fractyl Health Announces It Will Present Preclinical Data From Its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform At American Society Of Gene And Cell Therapy 2025 Annual Meeting May 13-17, 2025, In New Orleans, Louisiana.

GUTS

April 28, 2025
Read more →

Canaccord Genuity Initiates Coverage On Fractyl Health with Buy Rating, Announces Price Target of $12

GUTS

April 15, 2025
Read more →

Fractyl Health's Revita Could Be Key to Long-Term Weight Loss in Obesity Treatment, New Data Suggests

GUTS

April 1, 2025
Read more →

Fractyl Health Q4 GAAP EPS $(0.52) Misses $(0.34) Estimate, Sales $3.00K Miss $10.00K Estimate

GUTS

March 3, 2025
Read more →

Fractyl Health Reports Initial Results Showing Sustained Weight Maintenance After GLP-1 Discontinuation And Revita Treatment In First REVEAL-1 Cohort Patient

GUTS

January 13, 2025
Read more →

Fractyl Health To Present New Preclinical Data On Sustained Weight Maintenance And Blood Sugar From Its Rejuva RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate At ObesityWeek 2024

GUTS

November 4, 2024
Read more →

Fractyl Health Presents Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024

GUTS

May 20, 2024
Read more →